Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target reduced by research analysts at Truist Financial from $1,137.00 to $1,126.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s target price indicates a potential upside of 33.48% from the company’s previous close.

Other analysts have also issued research reports about the stock. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Royal Bank of Canada restated an “outperform” rating and set a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 22nd. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,090.24.

Regeneron Pharmaceuticals Trading Up 0.6 %

REGN stock opened at $843.60 on Friday. The company has a quick ratio of 4.62, a current ratio of 5.99 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $783.57 and a twelve month high of $1,211.20. The company has a market cap of $93.00 billion, a P/E ratio of 20.88, a PEG ratio of 2.88 and a beta of 0.15. The business has a fifty day moving average of $1,058.43 and a 200-day moving average of $1,039.88.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the company posted $8.79 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 37.46 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Brown Lisle Cummings Inc. lifted its stake in Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 10 shares during the last quarter. Sachetta LLC raised its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Adirondack Trust Co. lifted its stake in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares during the last quarter. UMB Bank n.a. grew its holdings in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares during the period. Finally, Team Hewins LLC increased its position in Regeneron Pharmaceuticals by 2.5% during the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 11 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.